This is a prospective, single-center, open-label, two-cohort clinical study evaluating the safety, tolerability, biodistribution, radiation dosimetry, and diagnostic performance of \[68Ga\]Ga-ELI411 PET imaging in adult patients with solid tumors. Eligible patients with an indication for 18F-FDG PET imaging will receive a single intravenous administration of \[68Ga\]Ga-ELI411 followed by serial PET imaging. Imaging findings will be compared with conventional imaging, histopathology, and clinical follow-up when applicable. The study will also evaluate tracer biodistribution, radiation dosimetry, and lesion detection performance compared with standard 18F-FDG PET imaging.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
18
For Cancer patients, subjects should have target FAP protein.
Union Hospital, Huazhong University of Science and Technology
Wuhan, Hubei, China
Semiquantitative SUV Parameters of Lesions on [68Ga]Ga-ELI411 PET
Semiquantitative imaging metrics measured from \[68Ga\]Ga-ELI411 PET lesions(SUVmax of target lesions).
Time frame: 7 days
Semiquantitative imaging metrics of Lesions on [68Ga]Ga-ELI411 PET
Semiquantitative imaging metrics (tumor-to-background ratios) of \[68Ga\]Ga-ELI411 PET lesions
Time frame: 7 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.